PHGE executed a 1-for-19 reverse stock split and its Israeli subsidiary BiomX Ltd. filed for insolvency proceedings, while the company's balance sheet deteriorated substantially.
The reverse stock split signals severe share price distress, as the company moved from a 1-for-10 split in 2024 to a much more aggressive 1-for-19 split in 2025. The insolvency filing of a wholly-owned subsidiary creates potential legal and financial complications, while the dramatic reduction in total assets suggests significant operational challenges or asset write-downs.
The company's financial position weakened markedly, with total assets declining 87% to $5.8M and cash falling 74% to $4.4M, indicating severe liquidity pressures. Operating cash flow improved modestly but remained deeply negative at -$26.4M, while R&D expenses declined 14% to $21.3M. The overall picture suggests a company in financial distress, burning through cash reserves while struggling to maintain operations.
Capex reduced 93.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Total assets contracted 86.6% — asset sales, write-downs, or balance sheet optimization underway.
Cash declined 74.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 72.8% — monitor working capital adequacy and short-term liquidity.
Operating cash flow grew 28.6% — strong conversion of earnings to cash, healthy business fundamentals.
Debt reduced 25.4% — deleveraging strengthens balance sheet and reduces financial risk.
Current liabilities reduced — improved short-term financial position and working capital health.
R&D spending cut 13.7% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →